Novartis: We cannot keep shipping Bexsero under investigational license

Novartis ($NVS) is trying to make its meningitis B vaccine Bexsero widely available in the U.S., instead of just supplying it on an ad hoc basis to tackle outbreaks. Bexsero was given to 5,000 students at Princeton University--and could be given to an additional 20,000 in California--but the Swiss drugmaker wants a more permanent solution for its currently unapproved vaccine. Speaking to investors following fourth quarter results--in which vaccine sales grew 6%--Novartis' vaccine chief Andrin Oswald said "we cannot keep on shipping it just under investigational use." Transcript

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.